Scan the QR code to watch the live broadcast.

On the evening of May 16, Beijing time, Jinbo Bio will hold a global launch conference on new technologies during the 78th Cannes Film Festival, and release its latest R&D results - the "Recombinant Type III Humanized Collagen Gel for Injection" (Guoshima No. 20253130751) product prepared using HiveCOL's "Honeycomb" collagen tissue network.

At the press conference, Jinbo Biotechnology will show in detail the research and development process, scientific principles and clinical applications of the "Honey Cell" collagen tissue network technology. According to Yang Xia, chairman of Jinbo Bio, the new product released this time has achieved a major technological innovation in the field of biofilling materials.

For more than ten years, Jinbo Bio has insisted on original innovation and continued to deepen its efforts in the field of humanized collagen, achieving many key breakthroughs. It is reported that the company has discovered and analyzed the core functional zone of human type III collagen for the first time in the world, and realized the large-scale production of type A recombinant humanized collagen; it was the first in China to be approved for injection-level recombinant collagen Class III medical devices, and applied type A recombinant humanized collagen to gynecology, dermatology, surgery and other fields. The recombinant type III humanized collagen gel product for injection released this time was approved for marketing by the State Food and Drug Administration on April 9, 2025.

What breakthroughs have been achieved by Jinbo Bio's new technology released this time? What are the significant advantages? How to empower beauty and health? This press conference will be broadcast globally through Jinbo Bio's official video account and media platform. Please stay tuned.

[Editor in charge: Wang Yuqi]